Presentation (CTI)

OBJECTIVES: To describe the economic outcomes resulting from the implementation of a rationalized and individualized treatment model in patients with complex respiratory diseases.
METHODS: This study was descriptive, observational, and retrospective, based on the analysis of medical records from patients treated during the years 2024 and 2025 at a specialized respiratory care institution. A therapeutic strategy focused on the rational use of medications was applied, with adjustments based on clinical progression and individualized patient follow-up. A univariate analysis was performed using measures of central tendency and relative and cumulative frequencies. Data processing was conducted using the R Core Team statistical software, version 4.5.0 (2025).
RESULTS: A total of 305 patients were evaluated, with a mean age of 51 years (SD: 18), of whom 61% were female. The most common diagnoses were severe asthma (58.7%), chronic rhinosinusitis with nasal polyposis (36.4%), and chronic obstructive pulmonary disease (COPD) (4.9%). Additionally, 86.2% of the patients were receiving biological therapy. The interventions included: avoidance of therapy initiation (54.4%), reduction in administration frequency (18%), complete treatment discontinuation (17%), change in drug treatment (6.2%), dose adjustments (3.6%) and switch to biosimilar medicine 0.7%. These measures resulted in total cost savings of USD 2,675,612.81. The main drugs associated with these interventions were dupilumab (45%, savings: USD 1,365,479.65), mepolizumab (18%, USD 567,268.80), omalizumab (12%, USD 279,898.99) and benralizumab (11%, USD 449,502.42)
CONCLUSIONS: The implementation of a rationalized and individualized treatment model in patients with complex respiratory diseases demonstrated a significant economic impact, achieving optimized resource utilization without compromising clinical effectiveness.